AUTHOR=D’Amato Maria , Paris Debora , Molino Antonio , Cuomo Paola , Fulgione Andrea , Sorrentino Nunzia , Palomba Letizia , Maniscalco Mauro , Motta Andrea 

TITLE=The Immune-Modulator Pidotimod Affects the Metabolic Profile of Exhaled Breath Condensate in Bronchiectatic Patients: A Metabolomics Pilot Study

JOURNAL=Frontiers in Pharmacology

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01115

DOI=10.3389/fphar.2019.01115

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> Pidotimod, a synthetic dipeptide molecule with biological and immunological activities, is used to reduce the number of exacerbations or pneumonitis in patients with inflammatory diseases.</p><p>In the present study, we investigated whether Pidotimod modifies the metabolomic pathways measured in the exhaled breath condensate (EBC) of non-cystic fibrosis bronchiectatic patients (NCFB).</p><p><bold>Materials and Methods:</bold> We analyzed 40 adult patients affected by NCFB. They were randomly selected to receive Pidotimod 800 mg b/d for 21 consecutive days (3 weeks) per month for 6 months (20 patients, V<sub>1</sub> group) or no drug (20 patients, V<sub>0</sub> group), with a 1:1 criterion and then followed as outpatients.</p><p><bold>Results:</bold> EBC samples were collected from all patients at baseline and after 6 months. They were investigated by combined nuclear magnetic resonance (NMR) spectroscopy and multivariate statistical analysis to uncover metabolic differences between EBC from NCFB patients before and after therapy with Pidotimod. Pulmonary function test and pulmonary exacerbations were analyzed at baseline and at the end of Pidotimod therapy.</p><p>The EBC metabolites were all identified, and through statistical evaluation, we were able to discriminate the two samples’ classes, with acetate, acetoin, lactate, and citrate as statistically significant discriminatory metabolites. The model vas validated by using a blind set of 20 NCFB samples, not included in the primary analysis.</p><p>No differences were observed in PFT after 6 months. At the end of the study, there was a significant decrease of exacerbation rate in V<sub>1</sub> group as compared with V<sub>0</sub> group, with a substantial reduction of the number of mild or severe exacerbations (<italic>p</italic> &lt; 0.001).</p><p><bold>Discussion:</bold> Pidotimod modifies the respiratory metabolic phenotype (“metabotype”) of NCFB patients and reduces the number of exacerbations.</p>